Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

NewAmsterdam Pharma Company N.V. - Ordinary Shares (NQ:NAMS)

35.84 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 29, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1
Open 35.84
Bid (Size) 33.02 (6)
Ask (Size) 37.20 (5)
Prev. Close 35.84
Today's Range 35.84 - 35.84
52wk Range 14.06 - 41.47
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
NewAmsterdam Pharma to Participate in Upcoming Medical Meeting and Investor Conferences in November
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
Deep Dive Into NewAmsterdam Pharma Co Stock: Analyst Perspectives (4 Ratings)
 
Via Benzinga

Performance

YTD
+38.0%
+38.0%
1 Month
+30.2%
+30.2%
3 Month
+59.8%
+59.8%
6 Month
+87.3%
+87.3%
1 Year
+88.9%
+88.9%

More News

Read More
NewAmsterdam Pharma to Present at the Stifel 2025 Virtual Cardiometabolic Forum
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
Expert Outlook: NewAmsterdam Pharma Co Through The Eyes Of 6 Analysts
Via Benzinga
NewAmsterdam Pharma to Participate in Upcoming Medical Meeting and Investor Conferences in September
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
NewAmsterdam Announces Acceptance of Marketing Authorization Applications for Review by European Medicine Agency for Obicetrapib
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
What 5 Analyst Ratings Have To Say About NewAmsterdam Pharma Co
Via Benzinga
NewAmsterdam (NAMS) Q2 Revenue Jumps 49%
Via The Motley Fool
NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
NewAmsterdam Pharma Presents Positive Data from BROADWAY Trial Demonstrating Statistically Significant Reductions in Key Alzheimer’s Disease Biomarkers at AAIC 2025
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
NewAmsterdam Pharma to Present Alzheimer’s Biomarker Data from BROADWAY Trial at AAIC 2025
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
What Analysts Are Saying About NewAmsterdam Pharma Co Stock
Via Benzinga
Analyst Says NewAmsterdam Stock Has Over 100% Upside, Citing 90% Success Probability For Obicetrapib
Via Benzinga
Get insights into the top gainers and losers of Monday's pre-market session.
Via Chartmill
NewAmsterdam Pharma Announces Positive Topline Alzheimer’s Disease Data from BROADWAY Clinical Trial
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
NewAmsterdam Pharma to Host R&D Day on June 11, 2025
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in June
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
NewAmsterdam Pharma to Present at the 2025 RBCCM Global Healthcare Conference
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
NewAmsterdam Pharma Announces Late-Breaking Data from BROADWAY and TANDEM Pivotal Studies Published in Leading Medical Journals and Presented at the European Atherosclerosis Society (EAS) Congress 2025
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
NewAmsterdam Pharma to Present New Clinical and Preclinical Data at 93rd EAS Congress
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
NewAmsterdam Pharma Appoints Adele Gulfo to its Board of Directors
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
The Analyst Verdict: NewAmsterdam Pharma Co In The Eyes Of 6 Experts
Via Benzinga

Frequently Asked Questions

Is NewAmsterdam Pharma Company N.V. - Ordinary Shares publicly traded?
Yes, NewAmsterdam Pharma Company N.V. - Ordinary Shares is publicly traded.
What exchange does NewAmsterdam Pharma Company N.V. - Ordinary Shares trade on?
NewAmsterdam Pharma Company N.V. - Ordinary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for NewAmsterdam Pharma Company N.V. - Ordinary Shares?
The ticker symbol for NewAmsterdam Pharma Company N.V. - Ordinary Shares is NAMS on the Nasdaq Stock Market
What is the current price of NewAmsterdam Pharma Company N.V. - Ordinary Shares?
The current price of NewAmsterdam Pharma Company N.V. - Ordinary Shares is 35.84
When was NewAmsterdam Pharma Company N.V. - Ordinary Shares last traded?
The last trade of NewAmsterdam Pharma Company N.V. - Ordinary Shares was at 10/29/25 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.